GlassScriptPhysician profile
Mansha U Kahloon
NPI 1265498745
$13,778.95
in general payments reported to CMS, 2019-2025
32 companies · $1,176 in 2025
The $1,176 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $485 · 2020: $1,185 · 2021: $515 · 2022: $976 · 2023: $4,861 · 2024: $4,581 · 2025: $1,176.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,869 · Travel and Lodging: $4,749.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,868.88 |
| Travel and Lodging | $4,749.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $7,490.03 | 2019-2025 | Aveir, Optis, Assurity |
| Novartis Pharmaceuticals Corporation | $1,362.08 | 2019-2025 | |
| Terumo Medical Corporation | $826.22 | 2020 | |
| Pfizer INC. | $793.94 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $703.89 | 2019-2025 | Brilinta, Farxiga, Andexxa |
| Amgen INC. | $681.21 | 2019-2025 | Repatha, Repatha |
| Merck Sharp & Dohme LLC | $340.47 | 2021-2025 | Verquvo |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $318.00 | 2019-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $272.68 | 2022-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $128.12 | 2022-2024 | Jardiance |
| Novo Nordisk INC | $111.88 | 2024-2025 | Wegovy, Ozempic |
| Biotronik INC. | $90.91 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $70.17 | 2021-2025 | Camzyos, Eliquis |
| Boston Scientific Corporation | $65.29 | 2022-2025 | Eluvia |
| Cvrx, INC. | $57.27 | 2024 | Barostim Neo System |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inari Medical, INC. | $55.12 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Bayer Healthcare Pharmaceuticals INC. | $49.46 | 2025 | |
| Sanofi-Aventis U.S. LLC | $41.73 | 2019-2024 | |
| Shockwave Medical, INC | $36.93 | 2022-2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Kestra Medical Technology Services, INC. | $36.72 | 2025 | Assure Wcd |
| Atricure, INC. | $31.69 | 2024-2025 | Atriclip Laa Exclusion System |
| Medtronic Vascular, INC. | $29.03 | 2019-2020 | |
| Cook Medical LLC | $25.71 | 2023 | Rosen |
| Kiniksa Pharmaceuticals, LTD. | $22.42 | 2022 | |
| Sun Pharmaceutical Industries INC. | $22.07 | 2023 | Odomzo, Blu-U |
| Kiniksa Pharmaceuticals International, Plc | $20.11 | 2024 | Arcalyst |
| Bard Peripheral Vascular, INC. | $19.60 | 2019 | |
| Acacia Pharma INC | $19.40 | 2022 | |
| Bridgebio Pharma, INC. | $16.54 | 2025 | Attruby |
| W. L. Gore & Associates, INC. | $14.70 | 2024 | Gore Viabahn Endoprosthesis With Heparin |
| Amarin Pharma, INC. | $14.70 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $10.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mansha Kahloon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.